HomeBiotech

Biotech

Mirador Therapeutics Licenses Long-Acting Anti-C5a Antibody from Kira Pharmaceuticals

Life Sciences Times - July 17, 2026

Biotech

Inflammasome Therapeutics Reports Positive Phase 2 Results for K8 in Geographic Atrophy

Life Sciences Times - July 17, 2026

Biotech

Syntis Bio Reports Positive Initial Phase 1/1b Data for Obesity Drug SYNT-101

Life Sciences Times - July 16, 2026

Biotech

Foundation Medicine Launches Initiative on Cancer Biomarker Test Quality

Life Sciences Times - July 16, 2026

Biotech

Alnylam Advances RNAi Neuroscience Programs in Alzheimer’s and Related Diseases

Life Sciences Times - July 15, 2026

Biotech

EdiGene Appointments Bo Zhang as Head of US Subsidiary and Kehua Fan Head of Business Development

Life Sciences Times - December 14, 2020 0

Biotech

Gilead Sciences to Acquire MYR GmbH

Life Sciences Times - December 12, 2020 0

Biotech

AstraZeneca to Acquire Alexion

Life Sciences Times - December 12, 2020 0

Biotech

Trailblazers: Vertex CEO Reshma Kewalramani on Leadership, STEM, Diversity, Inclusion and Medicine on Chai With Manju

Life Sciences Times - December 11, 2020 0

Biotech

Cell Isolation/ Separation Market Worth $15.0 Billion by 2025

Life Sciences Times - December 11, 2020 0

Biotech

LifeX Labs, Pittsburgh Life Sciences Greenhouse Teaming up to Fast-track Startups and Innovators

Life Sciences Times - December 7, 2020 0

Biotech

Life Sciences Leaders Optimistic About Funding Prospects but Cautious About Growth Outlook, New Research Finds

Life Sciences Times - December 7, 2020 0

1...99 100101Page 101 of 101

Mirador Therapeutics Licenses Long-Acting Anti-C5a Antibody from Kira Pharmaceuticals

July 17, 2026

Bayer and Henry Ford Health Partner to Expand Patient Access to Clinical Trials

July 17, 2026

Inflammasome Therapeutics Reports Positive Phase 2 Results for K8 in Geographic Atrophy

July 17, 2026

Aqemia and Sanofi Expand AI-Driven Drug Discovery Collaboration

July 17, 2026

Biotech

Mirador Therapeutics Licenses Long-Acting Anti-C5a Antibody from Kira Pharmaceuticals

Inflammasome Therapeutics Reports Positive Phase 2 Results for K8 in Geographic Atrophy

Syntis Bio Reports Positive Initial Phase 1/1b Data for Obesity Drug SYNT-101

Foundation Medicine Launches Initiative on Cancer Biomarker Test Quality

Alnylam Advances RNAi Neuroscience Programs in Alzheimer’s and Related Diseases

Most Read

Mirador Therapeutics Licenses Long-Acting Anti-C5a Antibody from Kira Pharmaceuticals

Bayer and Henry Ford Health Partner to Expand Patient Access to Clinical Trials

Inflammasome Therapeutics Reports Positive Phase 2 Results for K8 in Geographic Atrophy

Aqemia and Sanofi Expand AI-Driven Drug Discovery Collaboration

EDITOR PICKS

Inflammasome Therapeutics Reports Positive Phase 2 Results for K8 in Geographic Atrophy

Syntis Bio Reports Positive Initial Phase 1/1b Data for Obesity Drug SYNT-101

AdvanCell Raises $315 Million to Advance Targeted Alpha Cancer Therapies

THIS WEEK'S STORIES

Mirador Therapeutics Licenses Long-Acting Anti-C5a Antibody from Kira Pharmaceuticals

Immuto Scientific Identifies Potential Targets in Drug-Resistant Lung Cancer

Universal Brain Receives FDA Clearance for Rapid Brain-Function Assessment System

POPULAR CATEGORY

ABOUT US

FOLLOW US